Mulay James 4

What Happened

• James Mulay, a director of CG Oncology (CGON), exercised 24,165 derivative awards (options) at $26.63 per share on 2026-07-10 (cost $643,514) and immediately sold the 24,165 shares in the open market the same day at a weighted average price of $75.16 for gross proceeds of $1,816,241. The exercise/conversion of the derivative instrument is also reported (derivative disposed at $0), indicating the option was converted into shares and those shares were sold.
• This sequence (exercise then sale) resulted in roughly $1.17M in gross proceeds after subtracting the exercise cost (simple arithmetic: $1,816,241 − $643,514 = ~$1,172,727), before taxes/fees. The shares sold were fully vested.

Key Details

• Transaction date: July 10, 2026. Filing date: July 14, 2026 (filed 4 days after the transaction; appears to be later than the typical 2-business-day Form 4 deadline).
• Sale price: weighted average $75.16 per share (sales ranged from $74.98 to $75.79; filer will provide per-price breakdown on request).
• Exercise price/cost: $26.63 per share; total exercise cost reported $643,514.
• Shares sold/disposed: 24,165. Shares acquired via exercise: 24,165. Derivative converted/disposed reported at $0 (reflects exercise/conversion).
• Shares owned after transaction: not specified in the filing.
• Footnotes: Sales were executed under a Rule 10b5-1 trading plan adopted March 27, 2026 (F1). Shares were fully vested (F3). Price shown is a weighted average; range provided (F2).

Context

• This was an exercise of derivative awards followed by an immediate open-market sale (a common way for insiders to realize gains on vested options). Because the sales were executed under a prearranged 10b5-1 plan, they were pre-scheduled trades rather than ad-hoc market-timing decisions.
• The filing appears to have been submitted after the typical 2-business-day deadline for Form 4s; late filings can reduce short-term transparency but do not change the underlying transactions reported.